CAUTION: We have been advised that fraudulent emails with a modified domain name have been sent by a source purporting to be from Aird & Berlis LLP. These communications are not legitimate and are not from Aird & Berlis LLP. Disregard any such emails and do not engage with the sender or the email in any way. Please report the attempted fraud by contacting the Canadian Anti-Fraud Centre and by emailing Aird & Berlis LLP at help@airdberlis.com.

Back to all events
Sep 22, 2020: 15:00 - 16:00

The Science of Psychedelics: How Law & Science Support the Sector

CPD Information: 1 Substantive Hour for Lawyers

Sherri M. Altshuler, Jeffrey K. Merk and Erica L. Lowthers, PhD External Speakers:

Evan Levine - Co-Founder, CEO and Director, PsyBio Therapeutics
Darryl Hudson, PhD - Chief Science Officer, Sansero Life Sciences Inc.

 

ACCESS ARCHIVE

U.S. and Canadian laws have opened the door for scientists to explore alternative drugs such as ketamine, MDMA, LSD and psilocybin (i.e. magic mushrooms) as potential mental health treatments. Recent research has shown that these substances can have a multitude of positive effects on individuals suffering from Post-Traumatic Stress Disorder, depression, anxiety, addiction and chronic pain. While the science behind these findings is still evolving, scientists agree that a thin sheet of neurons within the brain's neocortex, called the claustrum, is receptive to psychedelic treatments. This part of the brain helps control subjective awareness, identity and the ego. Research patients report that certain psychedelics provide a sense of connectedness and focus after treatments, which can be beneficial for mental health.

As organizations, academic institutions, and corporations continue exploring these new alternative treatments, many are wondering where the future of this research is headed. What have studies on psychedelic medicine show us to date? How do lawyers, intellectual property experts and scientists work in unison on the legal aspects of this kind of research? How can researchers, capital markets participants and the community as a whole benefit from this field of study?

Join our panel of leading lawyers and psychedelic industry experts, as they provide insight on how science and law are working together to bring new mental health treatments to market.

For information regarding our webinars and communications, please contact:
Kassey Gonzales | rsvp@airdberlis.com | 416.865.3409

Should you experience any technical difficulties, we encourage you to review this help link to assist you in having an optimal webinar experience.

Related Industries

Related Events

Oct 21, 2021: 13:30 - 14:30
Events Uncovering Canadian Cryptocurrency Challenges CPD Information: 1 Substantive Hour for Lawyers Jack Bernstein, Saam Nainifard and Donald B. Johnston REGISTER HERE Encrypted digital currencies - or cryptocurrencies - have risen in popularity a...
Nov 4, 2021: 10:00 - 12:30
Events Workplace Law Education Session CPD Information: 2.5 Hours for HRPA and CHRP Members and 2.5 Substantive Hours for LSO Members Meghan A. Cowan, Michael F. Horvat, Alex Kagan, Lorenzo Lisi, Daria (Dasha) Peregoudova and Jessica Schissler CLICK TO REGISTER Join the Aird & Berlis Workplace Law Group for an interactive legal edu...
Oct 28, 2021: 15:00 - 16:00
Events Cannabis Sector Update: M&A, Financing, Legal Matters & More CPD Information: 1 Substantive Hour for Lawyers Jeffrey K. Merk and Sherri M. Altshuler REGISTER HERE In the first quarter of 2021, some of the cannabis industry's leading publicly l...